Israel Corp (ILCO) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Israel Corp ILS 33.94, price ILS 75.12, upside -54.8%, quality 32 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 4, 2026.
How to read this chart
60‑month range 75.12 ILA – 1,965 ILA · fair‑value band 22.17 ILA – 56.64 ILA · the 75.12 ILA price screens above the 33.94 ILA fair value. Dashed = 300-day average. As of Oct 4, 2026.
Follow Israel in your weekly email
Every Wednesday you see whether Israel is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Israel Corporation Ltd operates in the specialty minerals and chemical businesses.
Show more
Israel Corporation Ltd operates in the specialty minerals and chemical businesses. The company offers bromine and bromine-based compounds; salt, magnesium chloride, and other specialty mineral products; phosphorous based flame retardants and other phosphorus based specialty product; potash; magnesium; pure magnesium and magnesium alloys; chlorine and sylvinite; phosphate commodity products, such as phosphate rock and fertilizer-grade phosphoric acid; and phosphate-based fertilizers, as well as pure phosphoric acid. It also provides controlled release fertilizers, water soluble fertilizers, liquid fertilizers and straights, FertilizerpluS, soil and foliar micronutrients, secondary nutrients, bio-stimulants, soil conditioners, seed treatment products, and adjuvants. In addition, the company operates power plant that supplies electricity. It operates in Brazil, the United States, China, the United Kingdom, Germany, Spain, israel, France, India, Italy, and internationally. Israel Corporation ILtd was incorporated in 1968 and is based in Tel Aviv-Yafo, Israel.
Stock analysis
Israel Corp (ILCO) currently trades at 75.12 ILA, while our model-based Fair Value estimate is 33.94 ILA, 54.8% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of 79.84 ILA per share, and 6 of the 24 models we run sit above the 75.12 ILA price.
Bear case: the Growth DCF group reads lowest at 10.03 ILA, and 18 of the 24 models stay below the price. Evidence for this calculation is medium.
Scenario range: 22.17 ILA (bear) to 56.64 ILA (bull), the price of 75.12 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 32/100 (below-average quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Israel Corp reported revenue of $7.7B in FY2025 versus $7.0B in FY2021, a compound +2.7%/yr. Reported net income was $94.2M in FY2025, compounding +1.7%/yr from FY2021.
Key figures
Market cap 5.6B ILA · P/E ratio 14.6 · P/S ratio 0.18 · EPS (TTM) 5.13 ILA · Dividend yield 0.2% · Net margin 1.2% · Return on equity 5.1% · Return on assets (EBIT) 11.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 48 out of 100 (low confidence).
What moves the price
The share trades about 94% below its 52-week high and at its 52-week low.
For context, the median of 10 Basic Materials peers we cover trades at −39% fair-value upside, at −55%, ILCO screens richer than that median.
Fair Value models
Bear 22.17 ILAFair Value 33.94 ILABull 56.64 ILA
Price 75.12 ILA · Upside -54.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then (3.78 ILS per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.40/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+13.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−8.2%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.0%
Start year 2020 (pandemic). Over 10 years: +3.7% a year
Revenue growth 25 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−1.4%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
−4.7%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.9%
Dividend (yield on the price)0.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.9% vs −11.0%, picking up
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.4% → 8%
Start year 2020 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+31.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (figures in USD, USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +27.9% a year for the price.
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 713 stocks
Beats the industry median on 7/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score32 · Bottom 25%
Fair Value upside−54.8% · Below median
Profitability
Return on equity (TTM)5.1% · Below median
Return on assets10.5% · Top 25%
Net margin (TTM)4.7% · Below median
Operating margin (TTM)12.4% · Above median
Growth and dividend
Revenue growth16.5% · Above median
Dividend yield (TTM)0.2% · Bottom 25%
Balance sheet
Debt / equity0.73× · Highest 25%
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
P/E (TTM)14.6× · Cheaper than median
P/B0.61× · Cheapest 25%
P/S (TTM)0.70× · Cheaper than median
P/FCF22.7× · Pricier than median
EV/EBITDA7.6× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 0
FUTURE (revenue growth)83· sector 60
PAST (return on equity)20· sector 26
HEALTH (low debt)64· sector 95
DIVIDEND (yield)4· sector 28
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Israel Corp Fair Value". https://www.fairvalue-calculator.com/stock/ILCO
Frequently asked questions
Is Israel Corp (ILCO) overvalued or undervalued?
As of Oct 4, 2026, our model estimates a fair value of 33.94 ILA versus a price of 75.12 ILA, about −55% upside (overvalued).
What is the fair value of ILCO?
Our model-based fair value for Israel Corp is 33.94 ILA (as of Oct 4, 2026), built from audited fundamentals. The current price: 75.12 ILA.
What is the quality score of ILCO?
Israel Corp has a Quality Score of 32/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Israel Corp (ILCO)?
Our model-based price target is the fair value of 33.94 ILA (as of Oct 4, 2026) from 24 valuation models. Cautious scenario 22.17 ILA, optimistic scenario 56.64 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Israel Corp stock forecast for 2026?
Our models put fair value at 33.94 ILA, about −55% upside versus a price of 75.12 ILA (overvalued). Cautious scenario 22.17 ILA, optimistic scenario 56.64 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Israel Corp (ILCO)?
Israel Corp reported trailing-twelve-month revenue of about $7.7B (latest available figure, as of Oct 4, 2026).
Does Israel Corp pay a dividend?
Israel Corp currently shows a dividend yield of about 0.22% relative to its recent price (as of Oct 4, 2026).
What growth is priced into Israel Corp (ILCO)?
For today's price to be fair in a discounted-cash-flow model, Israel Corp would have to grow free cash flow by +31.0 % per year for five years (discount rate 11.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +9.0 % per year. As of Oct 4, 2026.
What discount rate (WACC) does the fair value of ILCO use?
Our models discount Israel Corp at 11.6 %: a base by market capitalisation (small), damped by beta 0.21, country premium for Israel. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Israel Corp that is +31.0 % per year a year over ten years, using the same discount rate (11.6 %) and the same formula as our fair value.
How much growth has Israel Corp (ILCO) delivered so far?
Over the past 5 years revenue at Israel Corp grew +9.0 % a year. The price currently implies +31.0 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Israel Corp (ILCO) growing?
The median revenue growth in the sector is +9.1 % a year. That is the yardstick for the growth priced into Israel Corp (+31.0 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Israel Corp (ILCO)?
The free-cash-flow yield on the price is 4.40 %: that much free cash flow Israel Corp produces per unit of market value. When it exceeds the discount rate of our models (11.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Israel Corp (ILCO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Israel Corp it is 33.94 ILA per share (as of Oct 4, 2026), against a price of 75.12 ILA. It is the blended result of 24 valuation models (cash flow, earnings, asset, dividend).
Is Israel Corp stock overvalued or undervalued in 2026?
As of Oct 4, 2026, ILCO trades above its calculated fair value: price 75.12 ILA, fair value 33.94 ILA, a gap of about −55% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ILCO?
No. The price is what the market pays today (75.12 ILA); the fair value is what the company's own numbers justify (33.94 ILA). For Israel Corp the two are 41.18 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Israel Corp worth?
The market values Israel Corp at about 5.6B ILA (market capitalisation, as of Oct 4, 2026). Per share that is 75.12 ILA; our models calculate a fair value of 33.94 ILA per share.
What do the bullish and bearish scenarios say about ILCO?
Our models span a range for Israel Corp: cautious scenario 22.17 ILA, base 33.94 ILA, optimistic 56.64 ILA per share (as of Oct 4, 2026, price 75.12 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ILCO?
Israel Corp trades at a price-to-earnings ratio of 14.6 (as of Oct 4, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of 33.94 ILA is built from several models across several years. Other multiples: P/B 0.6, P/S 0.7, EV/EBITDA 7.6.
How solid is the balance sheet of Israel Corp (ILCO)?
Balance-sheet figures for Israel Corp (as of Oct 4, 2026): return on equity 5.1%, debt of 0.73 per unit of equity. They feed the Quality Score of 32/100, which measures business quality independently of the share price.
How far is ILCO from its 52-week high?
Israel Corp trades at 75.12 ILA, about 94% below its 52-week high of 1,200 ILA and at the low of 75.12 ILA (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of 33.94 ILA is for.
Which stocks are comparable to Israel Corp?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Israel Corp stock attractive at the current price?
The data as of Oct 4, 2026: price 75.12 ILA, calculated fair value 33.94 ILA (−55%), Quality Score 32/100, from 24 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ILCO calculated?
We run Israel Corp through 24 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 33.94 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.0 % above its aggregate fair value. Israel Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Israel Corp (ILCO)?
The closing price on Oct 1, 2026 was 75.12 ILA. Our model-based fair value is 33.94 ILA, about −55% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Israel Corp right now?
The price sits above even our optimistic bull case (56.64 ILA). The favourable scenario is already priced in. Weak quality (32/100) and above fair value at the same time, the margin of safety is missing on both counts. A fairly wide model range (22.17 ILA to 56.64 ILA) leaves room in how you read the outcome.
Where does the earnings growth of Israel Corp (ILCO) come from?
Earnings per share at Israel Corp grew −5.0 % a year from 2014 to 2025. Broken into its drivers: revenue per share +2.8 %, EBIT margin −1.8 %, tax rate −4.9 %, residual (interest, one-offs) −1.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Israel Corp
How large is the market capitalisation of Israel Corp (ILCO)?
The market capitalisation of Israel Corp is 5.6B ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Israel Corp (ILCO)?
The price-to-sales ratio of Israel Corp is 0.18 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Israel Corp (ILCO)?
Earnings per share at Israel Corp are 5.13 ILA (price ÷ EPS = P/E 14.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Israel Corp (ILCO)?
The dividend yield of Israel Corp is 0.2% (payout 3.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Israel Corp (ILCO)?
The net margin of Israel Corp is 1.2% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Israel Corp (ILCO)?
The return on equity (ROE) of Israel Corp is 5.1% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Israel Corp (ILCO)?
On an EBIT basis the return on assets of Israel Corp is 11.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Israel Corp (ILCO)?
The operating margin of Israel Corp is 12.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Israel Corp (ILCO)?
Revenue at Israel Corp is growing +16.5% versus a year earlier (3y avg −8.2%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Israel Corp (ILCO)?
Earnings per share at Israel Corp are growing +24.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Israel Corp (ILCO) carry?
The net debt of Israel Corp is $2.9B (fiscal year 2025, ≈ 35.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Israel Corp in the live analysis
One click puts Israel Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Some data
Oct 4, 2026